Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of CCI-779 in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	18 and over	NCI	MDA-2003-0530 NCI-6182, NCT00075647, 6182

Trial Description

Purpose:

Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.

This phase II trial is studying how well CCI-779 works in treating patients with locally advanced or metastatic pancreatic cancer.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• No brain metastases
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive an infusion of CCI-779 once a week. Treatment may be repeated for as long as benefit is shown.

Patients will be evaluated every 3 months.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

M. D. Anderson Cancer Center at University of Texas

Henry Xiong, MD, PhD, Protocol chair(Contact information may not be current)		Ph: 713-792-6161; 800-392-1611
James Abbruzzese, MD, Protocol co-chair		Ph: 713-792-2828; 800-392-1611

Registry Information
Official Title		A Phase II Study of CCI-779 in Locally Advanced or Metastatic Pancreatic Cancer
Trial Start Date		2003-12-01
Registered in ClinicalTrials.gov		NCT00075647
Date Submitted to PDQ		2003-12-02
Information Last Verified		2005-02-08
NCI Grant/Contract Number		N01-CM17003, P30-CA16672

Back to Top